GW Pharmaceuticals Profit Margin 2013-2018 | GWPH
Current and historical gross margin, operating margin and net profit margin for GW Pharmaceuticals (GWPH) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. GW Pharmaceuticals net profit margin as of September 30, 2018 is -1734.86%.
|GW Pharmaceuticals Annual Profit Margins
|GW Pharmaceuticals Quarterly Profit Margins
||Medical Products Manufacturing
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.